NASDAQ · LFCR
Lifecore Biomedical, Inc.
$6.39-$0.13 (-2.0%)
Lifecore Biomedical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.85% below the high.
Loading market information…
NASDAQ · ALIM · USD
Stock price, earnings
Quote as of Sep 13, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Alimera Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alimera Sciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2023 | May 15, 2023 | -$0.71-22.41% vs estimate | $13.55M-10.59% vs estimate |
|---|
| Q4 2022 | Mar 31, 2023 | -$0.54-92.86% vs estimate | $14.03M-4.04% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.39-$0.13 (-2.0%)
Lifecore Biomedical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.85% below the high.
$5.14-$0.27 (-4.99%)
Journey Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 46.23% below the high.
$0.77-$0.05 (-6.18%)
Organogenesis Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.15% below the high.
$0.62-$0.03 (-4.48%)
China Pharma Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.76% below the high.
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
$4.61-$0.62 (-11.85%)
Shuttle Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.62% below the high.
$0.78+$0.01 (+0.85%)
Adamis Pharmaceuticals Corporation’s quoted price sits in the lower half of its reported 52-week range, 96.43% below the high.
$0.34-$0.06 (-14.97%)
Mallinckrodt plc’s quoted price sits in the lower half of its reported 52-week range, 97.87% below the high.
